Windward Bio Group AG has made a significant disclosure regarding ownership in its recent SEC filing. The filing, dated November 12, 2026, details the ownership stakes held by director Otello Stampacchia, which is vital for the company's governance and transparency.

Understanding ownership structures is crucial for investors, particularly in the biological products sector, where trust and clarity can significantly impact market perception. This filing underscores Windward's commitment to maintaining open communication with stakeholders.

Background

Windward Bio Group AG operates in the biological products industry, specifically classified under SIC 2836, which focuses on biological products excluding diagnostic substances. The company is publicly traded under the ticker WWB, although it is not listed on a U.S. exchange. The firm is incorporated in V8 and has its business address in Basel, Switzerland.

What the Filing Says

The SEC filing reveals that Otello Stampacchia, a director at Windward, has reported ownership of various preferred shares. The filing indicates that Stampacchia does not hold any direct securities but has significant indirect ownership through two funds, Omega Fund VII, L.P. and Omega Fund VIII, L.P. Each fund holds Series A and Series B preferred shares convertible into common shares.

"Each Series A Preferred Share and Series B Preferred Share will automatically convert into the number of Common Shares on a 1 to 1 basis immediately prior to the closing of the Issuer's initial public offering and has no expiration date."

Impact

This ownership disclosure is particularly relevant for investors and stakeholders in Windward Bio Group AG. It highlights the involvement of significant investment entities in the company's governance structure, which may influence investor sentiment and confidence. Transparency in ownership can foster trust and potentially attract further investment.

What's Next

The filing does not say what happens next.